The Motley Fool
23 Aug 2026, 11:14 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Cardinal Health's Pharmaceutical and Specialty Solutions segment reported a 21% increase in profit to $645 million in the fourth quarter. — Strong bottom-line growth in a core segment typically drives positive investor sentiment and stock price appreciation.
+0.60Cardinal Health guides fiscal 2027 segment revenue growth of 3% to 5% and profit growth of 8% to 11%. — Forward guidance provides a baseline for valuation, though the projected growth is moderate.
+0.40Deborah Weitzman, CEO of the PSS Segment, sold 7,354 shares of Cardinal Health (CAH) at a weighted average price of $235.45. — Insider selling can be seen as a bearish signal, but the impact is neutralized here by the fact that she increased her overall holdings via performance units.
-0.10Which stocks this story touches
Continue reading
6 related stories
Search tags
Strong financial performance in the Pharmaceutical and Specialty Solutions segment with significant profit growth and positive forward guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1h ago
